Abstract Library

#2922 Clinicopathological Characteristics of Borderline Pulmonary Neuroendocrine Neoplasms

Introduction: According to the WHO 2015 classification pulmonary neuroendocrine neoplasms (NENs) are subdivided in carcinoids and neuroendocrine carcinoma (small cell lung carcinoma and large cell neuroendocrine carcinoma (LCNEC)), based on the presence of necrosis and mitotic index (MI). However, in some NENs a discrepancy is observed between grade of differentiation and proliferation rate.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Hermans B, Derks J, Moonen L, Habraken C, von der Thusen J,

Keywords: Borderline tumor, NET grade 3, LCNEC, atypical carcinoid, WHO-classification,

#2276 Ki-67 to Predict Recurrence and Survival of Pancreatic Neuroendocrine Tumors

Introduction: Despite evidence of different malignant potential, postoperative follow-up is similar for G1 and G2 pancreatic neuroendocrine tumors (panNET) and adjuvant treatment is currently not indicated.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Genc C, Falconi M, Partelli S, Muffatti F, Van Eeden S,

Keywords: Neuroendocrine tumors, pancreas, recurrence, survival, Ki-67 proliferation index, prognosis,

#1379 Evaluation of the Concordance Between the Stage of the Disease and Ki-67 Proliferation Index in Gastroenteropancretic Neuroendocrine Tumors (GEP-NETs)

Introduction: .

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Özaslan E

Authors: Özaslan E, Demir S, Karaca H, Güven K,

Keywords: grade,stage,NET,

#916 PET+10 Study: Efficacy of Platin/Etoposide Combination in Well-Differentiated Pancreatic Neuroendocrine Tumors with Ki-67 ≥ 10%

Introduction: Platin-etoposide (PE), the gold standard regimen for poorly differentiated neuroendocrine carcinomas, might be effective in well-differentiated pancreatic neuroendocrine tumors (WD-PNETs) with a high Ki-67 proliferation index.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: BAUDIN E

Authors: Roquin G, Baudin E, Lombard-Bohas C, Cadiot G, Dominguez S,

Keywords: platin/etoposide, pNETs, Ki-67,

#845 Ki-67 Index as a Biomarker of Response to Cytotoxic Chemotherapy

Introduction: Chemotherapy (CT) is widely used for neuroendocrine tumors (NET) but there are no validated biomarkers to predict response. The Ki-67 proliferation index has been proposed as a means of selecting patients for CT but robust data are lacking.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Childs A, Kirkwood A, Lee A, Caplin M, Gillmore R,

Keywords: chemotherapy, Ki-67,